No physician may be subject to disciplinary action by the North Dakota board of medicine for prescribing or administering amygdalin to a patient under the physician’s care who has requested the substance unless the board, in a hearing conducted pursuant to chapter 28-32, has made a formal finding that the substance is harmful.